Holen Sie sich die Stockscreener-App
18.32
0.38%
-0.04
Schlusskurs vom Vortag:
$18.28
Offen:
$18.21
24-Stunden-Volumen:
2,426
Relative Volume:
0.01
Marktkapitalisierung:
$692.22M
Einnahmen:
$89.06M
Nettoeinkommen (Verlust:
$-53.41M
KGV:
-12.54
EPS:
-1.4612
Netto-Cashflow:
$-42.48M
1W Leistung:
+2.48%
1M Leistung:
-11.47%
6M Leistung:
+57.53%
1J Leistung:
-21.61%
1-Tages-Spanne:
$18.21
$18.40
1-Wochen-Bereich:
$17.36
$18.87
52-Wochen-Spanne:
$10.01
$24.33
Ceribell Inc Stock (CBLL) Company Profile
Firmenname
Ceribell Inc
Sektor
Branche
Telefon
(800) 436-0826
Adresse
360 N. PASTORIA AVENUE, SUNNYVALE
Compare CBLL vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
18.39 | 688.08M | 89.06M | -53.41M | -42.48M | -1.4612 |
|
ABT
Abbott Laboratories
|
110.20 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
358.70 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
90.19 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.89 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.54 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Raymond James | Strong Buy |
| 2025-06-24 | Eingeleitet | BTIG Research | Buy |
| 2025-04-04 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-11-05 | Eingeleitet | BofA Securities | Buy |
| 2024-11-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Ceribell Inc Aktie (CBLL) Neueste Nachrichten
Ceribell’s Woo sells $202k in shares - Investing.com Nigeria
Foehr David, senior VP at Ceribell, sells $81k in CBLL stock - Investing.com Nigeria
CeriBell Conference: CFO Highlights 36% Revenue Growth, Expands EEG Platform to Pediatrics and Delirium - Yahoo Finance
CeriBell Highlights 2026 Growth Plan at TD Cowen: 25%-29% Guide, VA Ramp, Delirium Pilot - Yahoo Finance
CeriBell (NASDAQ:CBLL) CEO Sells $680,550.00 in Stock - MarketBeat
CeriBell (NASDAQ:CBLL) Director Rebecca Robertson Sells 827 Shares - MarketBeat
David Foehr Sells 4,560 Shares of CeriBell (NASDAQ:CBLL) Stock - MarketBeat
Robertson sells Ceribell (CBLL) shares worth $14,720 - Investing.com Nigeria
Ceribell CEO Chao sells $680k in CBLL stock - Investing.com India
Ceribell Earnings Call Highlights Strong Growth, Rising Costs - TipRanks
Ceribell’s Woo sells $202k in shares By Investing.com - Investing.com Australia
CeriBell (NASDAQ:CBLL) CTO Sells $147,587.75 in Stock - MarketBeat
CeriBell, Inc. (NASDAQ:CBLL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Cautious Guidance Offsets Solid Q4 for CeriBell, Inc. (CBLL), Says Canaccord - Insider Monkey
CeriBell, Inc. (CBLL) Stock Analysis: Exploring a 43% Potential Upside in the Innovative Medical Devices Sector - DirectorsTalk Interviews
CBLL Should I Buy - Intellectia AI
CeriBell (CBLL) Revenue Growth To US$24.8m Tests Premium Valuation Narrative - simplywall.st
Earnings Call Summary | Ceribell(CBLL.US) Q4 2025 Earnings Conference - 富途牛牛
Top Ceribell Executives Quietly Unload Shares in Coordinated Insider Move - TipRanks
Insider Selling: CeriBell (NASDAQ:CBLL) VP Sells 569 Shares of Stock - MarketBeat
Insider Selling: CeriBell (NASDAQ:CBLL) CTO Sells 705 Shares of Stock - MarketBeat
CeriBell (NASDAQ:CBLL) VP David Foehr Sells 781 Shares - MarketBeat
Insider Selling: CeriBell (NASDAQ:CBLL) CFO Sells 808 Shares of Stock - MarketBeat
[Form 4] Ceribell, Inc. Insider Trading Activity - Stock Titan
Ceribell: Strong Q4 Beat, Multi-Year Growth Drivers, and Clear Path to Profitability Support Buy Rating - TipRanks
CeriBell (NASDAQ:CBLL) Shares Gap DownTime to Sell? - MarketBeat
Ceribell Inc. debuts AI-enabled neonatal EEG at NEO Pediatrix Conference - Traders Union
CeriBell revenue up 34% to USD 24.8M in Q4 2025 - Medical Buyer
CeriBell Q4 Revenue Rises 34%; Projects Revenue Growth Of 25%-29% For FY'26 - Nasdaq
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results - The Globe and Mail
CeriBell (CBLL) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ceribell: Strong Top-Line Outperformance and Expanding Growth Vectors Underpin Buy Rating - TipRanks
CeriBell Q4 Earnings Call Highlights - Yahoo Finance
CeriBell, Inc. (CBLL) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq
CeriBell, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Ceribell Inc (NASDAQ:CBLL) Reports Strong Q4 Revenue Beat and Provides 2026 Outlook - ChartMill
Ceribell Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ceribell beats Q4 revenue expectations - TradingView
Ceribell, Inc. SEC 10-K Report - TradingView
CeriBell, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Ceribell (NASDAQ: CBLL) posts 36% 2025 revenue growth but wider net loss - Stock Titan
Earnings Flash (CBLL) Ceribell, Inc. Reports Q4 Revenue $24.8M, vs. FactSet Est of $23.9M - marketscreener.com
CeriBell, Inc. (CBLL) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Institution Moves: Why is CeriBell Inc stock going upWatch List & Fast Moving Stock Watchlists - baoquankhu1.vn
CeriBell's Earnings: A Preview - Benzinga
Josef Parvizi Sells 16,714 Shares of CeriBell (NASDAQ:CBLL) Stock - MarketBeat
Ceribell (CBLL) director Parvizi sells $338,792 in shares - Investing.com South Africa
Ceribell (CBLL) director Parvizi sells $338,792 in shares By Investing.com - Investing.com UK
Ceribell Insider Sold Shares Worth $338,793, According to a Recent SEC Filing - marketscreener.com
CeriBell Inc (CBLL) Q4 2025: Everything You Need To Know Ahead O - GuruFocus
Ceribell, Inc. (CBLL) Receives a Buy from BTIG - The Globe and Mail
Finanzdaten der Ceribell Inc-Aktie (CBLL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.69%
1.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):